These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phytocompounds of Rolta R; Salaria D; Sharma P; Sharma B; Kumar V; Rathi B; Verma M; Sourirajan A; Baumler DJ; Dev K Curr Pharmacol Rep; 2021; 7(4):135-149. PubMed ID: 34306988 [TBL] [Abstract][Full Text] [Related]
3. Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach. Ambrose JM; Kullappan M; Patil S; Alzahrani KJ; Banjer HJ; Qashqari FSI; Raj AT; Bhandi S; Veeraraghavan VP; Jayaraman S; Sekar D; Agarwal A; Swapnavahini K; Krishna Mohan S Molecules; 2022 Mar; 27(6):. PubMed ID: 35335139 [TBL] [Abstract][Full Text] [Related]
4. Molecular insights into the interaction of eighteen different variants of SARS-CoV-2 spike proteins with sixteen therapeutically important phytocompounds: in silico approach. Batra B; Srinivasan S; Gopalakrishnan SG; Patel CN; Kumar V; Sourirajan A; Dev K J Biomol Struct Dyn; 2023; 41(22):12880-12907. PubMed ID: 36690609 [TBL] [Abstract][Full Text] [Related]
5. Potential of phytocompounds from Jose S; Gupta M; Sharma U; Quintero-Saumeth J; Dwivedi M J Mol Struct; 2022 Apr; 1254():132369. PubMed ID: 35034979 [TBL] [Abstract][Full Text] [Related]
7. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods. Ebrahimi M; Karami L; Alijanianzadeh M Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285 [TBL] [Abstract][Full Text] [Related]
8. Pandey AK; Verma S Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723 [TBL] [Abstract][Full Text] [Related]
9. Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study. Aatif M; Muteeb G; Alsultan A; Alshoaibi A; Khelif BY Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33922914 [TBL] [Abstract][Full Text] [Related]
10. Comparative docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2. Chugh A; Sehgal I; Khurana N; Verma K; Rolta R; Vats P; Salaria D; Fadare OA; Awofisayo O; Verma A; Phartyal R; Verma M 3 Biotech; 2023 Jan; 13(1):36. PubMed ID: 36619821 [TBL] [Abstract][Full Text] [Related]
11. Exploring the inhibitory potential of Houchi S; Messasma Z J Mol Struct; 2022 Sep; 1263():133032. PubMed ID: 35431327 [TBL] [Abstract][Full Text] [Related]
12. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003 [TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
14. Naringenin-4'-glucuronide as a new drug candidate against the COVID-19 Omicron variant: a study based on molecular docking, molecular dynamics, MM/PBSA and MM/GBSA. Cobre AF; Maia Neto M; de Melo EB; Fachi MM; Ferreira LM; Tonin FS; Pontarolo R J Biomol Struct Dyn; 2024 Jul; 42(11):5881-5894. PubMed ID: 37394802 [TBL] [Abstract][Full Text] [Related]
15. Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach. Mathew SM; Benslimane F; Althani AA; Yassine HM Qatar Med J; 2021; 2021(1):12. PubMed ID: 34604010 [No Abstract] [Full Text] [Related]
16. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation. Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226 [TBL] [Abstract][Full Text] [Related]
17. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19. Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986 [TBL] [Abstract][Full Text] [Related]
18. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach. Zaheer M; Ali N; Javed H; Munir R; Jamil N J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991 [TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2. Naik SR; Bharadwaj P; Dingelstad N; Kalyaanamoorthy S; Mandal SC; Ganesan A; Chattopadhyay D; Palit P J Biomol Struct Dyn; 2022 Sep; 40(15):6921-6938. PubMed ID: 33682632 [TBL] [Abstract][Full Text] [Related]
20. Identification of new pharmacophore against SARS-CoV-2 spike protein by multi-fold computational and biochemical techniques. Ullah A; Ullah S; Halim SA; Waqas M; Ali B; Ataya FS; El-Sabbagh NM; Batiha GE; Avula SK; Csuk R; Khan A; Al-Harrasi A Sci Rep; 2024 Feb; 14(1):3590. PubMed ID: 38351259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]